Form 4: Alignment Healthcare CMO Sells Shares

Alignment Healthcare's Chief Medical Officer, Hyong Kim, sold a total of 85,034 shares of common stock in two transactions in October 2025, including shares for tax obligations and under a 10b5-1 plan.

Summary

• Hyong Kim, Chief Medical Officer of Alignment Healthcare, Inc. (ALHC), reported two sales of common stock.
• On October 8, 2025, 33,655 shares were sold at a price of $17.29 per share to cover tax withholding obligations related to restricted stock unit vesting, which was a non-discretionary transaction.
• On October 9, 2025, an additional 51,379 shares were sold at a price of $17.5713 per share.
• The second sale was executed pursuant to a Rule 10b5-1 plan adopted on March 14, 2025.
• Following these transactions, Hyong Kim beneficially owns 362,333 shares of common stock directly.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While insider selling can sometimes be perceived negatively, the sales are attributed to non-discretionary tax obligations and a pre-arranged 10b5-1 trading plan, which mitigates concerns about management's outlook on the company.

Positives

• The sale of 33,655 shares was non-discretionary, solely to cover tax withholding obligations from restricted stock unit vesting, indicating a routine compensation event rather than a discretionary divestment.
• The sale of 51,379 shares was conducted under a pre-arranged Rule 10b5-1 trading plan, which was adopted on March 14, 2025, suggesting a planned liquidity event rather than a reaction to recent company performance or outlook.

Negatives

• The aggregate sale of 85,034 shares by a Chief Medical Officer represents a reduction in insider ownership, which some investors may view with caution, despite the stated reasons for the sales.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This insider transaction report is specific to Alignment Healthcare and its Chief Medical Officer. It does not provide broader industry context or trends.

Stakeholder Impact

• Shareholders: The sale of shares by a key executive could be interpreted in various ways, but the stated reasons (tax obligations, 10b5-1 plan) suggest it is not indicative of a negative outlook on the company's future. It provides liquidity for the executive and is a routine part of executive compensation.

Key Dates

Recommendation

The reported insider sales are primarily for tax withholding obligations and under a pre-established 10b5-1 trading plan. These are typically routine and non-discretionary events for executives, rather than signals of a change in the company's fundamental prospects or management's confidence. Therefore, this Form 4 filing alone does not provide sufficient new information to warrant a change from a 'hold' recommendation, as it does not reflect a discretionary negative view from the insider.

Keywords

Alignment Healthcare, ALHC, Insider Trading, Form 4, Stock Sale, Chief Medical Officer, Hyong Kim, 10b5-1 Plan, Restricted Stock Units